Literature DB >> 27911124

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.

Vibe Skov1, Caroline Hasselbalch Riley1,2, Mads Thomassen3, Lasse Kjær1, Thomas Stauffer Larsen4, Ole Weis Bjerrum5, Torben A Kruse3, Hans Carl Hasselbalch1.   

Abstract

Gene expression profiling in Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) have unraveled significant deregulation of several immune and inflammation genes of potential importance for clonal evolution. Other mechanisms might be downregulation of major histocompatibility class I and II genes used by tumor cells to escape antitumor T-cell-mediated immune responses. Several genes encoding human leukocyte antigen (HLA) class I and II molecules have been shown to be significantly downregulated. Upregulation of HLA genes is considered one of the mechanisms of action of interferon (IFN)-alpha2, but regulation of these genes during IFN-alpha2 treatment in MPNs has never been studied. Our findings show a significant upregulation of several HLA genes of importance for tumor immune surveillance by IFN-alpha2 treatment in MPNs. This mechanism might enhance the cytotoxic potential of immune cells against MPNs and explain the induction of minimal residual disease by IFN-alpha2 treatment in these patients.

Entities:  

Keywords:  HLA genes; Interferon-alpha2; myeloproliferative neoplasms; tumor immune surveillance; whole blood transcriptional profiling

Mesh:

Substances:

Year:  2016        PMID: 27911124     DOI: 10.1080/10428194.2016.1262032

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 2.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

3.  Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature.

Authors:  Samah Alimam; William Villiers; Richard Dillon; Michael Simpson; Manohursingh Runglall; Alexander Smith; Prodromos Chatzikyriakou; Paul Lavender; Anju Kanda; Ken Mills; Beatriz Bellosillo Paricio; James Kaufman-Cook; Sophie Ord; Shahram Kordasti; Deepti Radia; Claire Woodley; Yvonne Francis; Ghulam Mufti; Donal P McLornan; Claire N Harrison
Journal:  Blood Adv       Date:  2021-02-23

4.  Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.

Authors:  Vibe Skov; Mads Thomassen; Lasse Kjær; Christina Ellervik; Morten Kranker Larsen; Trine Alma Knudsen; Torben A Kruse; Hans C Hasselbalch
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

5.  The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Authors:  M O Holmström; E Martinenaite; S M Ahmad; Ö Met; C Friese; L Kjær; C H Riley; P Thor Straten; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2017-07-05       Impact factor: 11.528

6.  MAPK14 over-expression is a transcriptomic feature of polycythemia vera and correlates with adverse clinical outcomes.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Min Wang; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  J Transl Med       Date:  2021-05-31       Impact factor: 5.531

Review 7.  Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.

Authors:  Uffe Klausen; Staffan Holmberg; Morten Orebo Holmström; Nicolai Grønne Dahlager Jørgensen; Jacob Handlos Grauslund; Inge Marie Svane; Mads Hald Andersen
Journal:  Front Immunol       Date:  2018-10-01       Impact factor: 7.561

8.  Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms.

Authors:  Jacob Handlos Grauslund; Morten Orebo Holmström; Nicolai Grønne Jørgensen; Uffe Klausen; Stine Emilie Weis-Banke; Daniel El Fassi; Claudia Schöllkopf; Mette Borg Clausen; Lise Mette Rahbek Gjerdrum; Marie Fredslund Breinholt; Julie Westerlin Kjeldsen; Morten Hansen; Steffen Koschmieder; Nicolas Chatain; Guy Wayne Novotny; Jesper Petersen; Lasse Kjær; Vibe Skov; Özcan Met; Inge Marie Svane; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

9.  Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients.

Authors:  Michelino Di Rosa; Cesarina Giallongo; Alessandra Romano; Daniele Tibullo; Giovanni Li Volti; Giuseppe Musumeci; Ignazio Barbagallo; Rosa Imbesi; Paola Castrogiovanni; Giuseppe A Palumbo
Journal:  Int J Mol Sci       Date:  2020-04-22       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.